Phathom Pharmaceuticals (PHAT) Competitors $8.37 +0.23 (+2.83%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PHAT vs. NAMS, IDYA, CNTA, RXRX, IBRX, APGE, WVE, MIRM, AKRO, and AMPHShould you be buying Phathom Pharmaceuticals stock or one of its competitors? The main competitors of Phathom Pharmaceuticals include NewAmsterdam Pharma (NAMS), IDEAYA Biosciences (IDYA), Centessa Pharmaceuticals (CNTA), Recursion Pharmaceuticals (RXRX), ImmunityBio (IBRX), Apogee Therapeutics (APGE), Wave Life Sciences (WVE), Mirum Pharmaceuticals (MIRM), Akero Therapeutics (AKRO), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry. Phathom Pharmaceuticals vs. NewAmsterdam Pharma IDEAYA Biosciences Centessa Pharmaceuticals Recursion Pharmaceuticals ImmunityBio Apogee Therapeutics Wave Life Sciences Mirum Pharmaceuticals Akero Therapeutics Amphastar Pharmaceuticals NewAmsterdam Pharma (NASDAQ:NAMS) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, community ranking, institutional ownership and media sentiment. Which has higher earnings & valuation, NAMS or PHAT? NewAmsterdam Pharma has higher revenue and earnings than Phathom Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$33.59M73.18-$176.94MN/AN/APhathom Pharmaceuticals$26.27M21.79-$201.59M-$5.69-1.47 Does the MarketBeat Community believe in NAMS or PHAT? Phathom Pharmaceuticals received 67 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 72.13% of users gave Phathom Pharmaceuticals an outperform vote. CompanyUnderperformOutperformNewAmsterdam PharmaOutperform Votes21100.00% Underperform VotesNo VotesPhathom PharmaceuticalsOutperform Votes8872.13% Underperform Votes3427.87% Do institutionals and insiders hold more shares of NAMS or PHAT? 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 19.5% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 24.1% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is NAMS or PHAT more profitable? NewAmsterdam Pharma has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -1,292.14%. Company Net Margins Return on Equity Return on Assets NewAmsterdam PharmaN/A N/A N/A Phathom Pharmaceuticals -1,292.14%N/A -79.57% Does the media prefer NAMS or PHAT? In the previous week, NewAmsterdam Pharma had 11 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 26 mentions for NewAmsterdam Pharma and 15 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 0.73 beat NewAmsterdam Pharma's score of 0.73 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 11 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phathom Pharmaceuticals 4 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate NAMS or PHAT? NewAmsterdam Pharma presently has a consensus price target of $36.20, indicating a potential upside of 36.04%. Phathom Pharmaceuticals has a consensus price target of $23.00, indicating a potential upside of 174.79%. Given Phathom Pharmaceuticals' higher possible upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than NewAmsterdam Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more risk & volatility, NAMS or PHAT? NewAmsterdam Pharma has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. SummaryNewAmsterdam Pharma beats Phathom Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Ad Brownstone ResearchDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAT vs. The Competition Export to ExcelMetricPhathom PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$572.32M$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-1.4710.80135.3117.54Price / Sales21.79287.861,260.42139.42Price / CashN/A56.6540.5837.95Price / Book-6.595.394.884.92Net Income-$201.59M$152.04M$118.89M$225.78M7 Day Performance-0.36%-4.32%15.96%-1.56%1 Month Performance-5.85%2.80%15.87%6.68%1 Year Performance2.95%17.30%34.78%22.48% Phathom Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHATPhathom Pharmaceuticals2.9338 of 5 stars$8.37+2.8%$23.00+174.8%-4.0%$572.32M$26.27M-1.47110Gap UpNAMSNewAmsterdam Pharma2.5475 of 5 stars$24.60-0.4%$36.20+47.2%+147.8%$2.27B$33.59M0.0057Insider TradeIDYAIDEAYA Biosciences4.3729 of 5 stars$25.89+2.8%$53.67+107.3%-24.9%$2.24B$3.92M-10.8180Analyst ForecastShort Interest ↓CNTACentessa Pharmaceuticals3.3199 of 5 stars$16.37-1.2%$25.83+57.8%+147.5%$2.16B$6.85M-10.8372Insider TradeNews CoverageRXRXRecursion Pharmaceuticals2.5201 of 5 stars$7.50+7.9%$9.25+23.3%-26.6%$2.15B$44.58M-4.85400IBRXImmunityBio2.2703 of 5 stars$3.04+5.9%$17.38+471.5%-34.2%$2.12B$7.33M-3.36590APGEApogee Therapeutics2.7252 of 5 stars$46.39+4.2%$83.88+80.8%+110.6%$2.09BN/A-18.3991Insider TradeShort Interest ↑News CoverageWVEWave Life Sciences4.9155 of 5 stars$13.63+1.4%$22.22+63.0%+227.7%$2.08B$113.31M-12.11240Positive NewsMIRMMirum Pharmaceuticals4.1617 of 5 stars$42.53+0.2%$57.73+35.7%+22.1%$2.04B$307.03M-21.01140AKROAkero Therapeutics3.958 of 5 stars$29.13+0.8%$46.83+60.8%+33.6%$2.03BN/A-7.7030Short Interest ↓AMPHAmphastar Pharmaceuticals4.8676 of 5 stars$41.09-2.7%$60.33+46.8%-27.8%$1.98B$644.40M14.081,761Insider Trade Related Companies and Tools Related Companies NewAmsterdam Pharma Alternatives IDEAYA Biosciences Alternatives Centessa Pharmaceuticals Alternatives Recursion Pharmaceuticals Alternatives ImmunityBio Alternatives Apogee Therapeutics Alternatives Wave Life Sciences Alternatives Mirum Pharmaceuticals Alternatives Akero Therapeutics Alternatives Amphastar Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PHAT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
